Sulfonamide-based acyclic and conformationally constrained MMP inhibitors: From computer-assisted design to nanomolar compounds

Current Topics in Medicinal Chemistry

Volumn 4, Issue 12, 2004, Pages 1269-1287

  Hanessian, Stephen ^a   Moitessier, Nicolas ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NANCY UNIVERSITÉ   (France)

Author keywords

Aziridine; Computer assisted design; Constrained hydroxamic acids; MMP inhibitors; Pyrrolidine; Tetrahydrofuran

Indexed keywords

3 PYRIDYLOXYMETHYL ETHER; 4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; ALICYCLIC HYDROCARBON; AZIRIDINE DERIVATIVE; BATIMASTAT; BENZENE DERIVATIVE; CGS 27023A; CIPEMASTAT; COLLAGENASE 3; CYCLOPROPANE DERIVATIVE; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PRINOMASTAT; PYRROLIDINE DERIVATIVE; REBIMASTAT; SUCCINIC ACID DERIVATIVE; SULFONAMIDE; TETRAHYDROFURAN DERIVATIVE; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AUTOMATION; BINDING AFFINITY; CANCER THERAPY; CLINICAL TRIAL; COMPUTER AIDED DESIGN; DRUG BINDING SITE; DRUG CONFORMATION; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; MOLECULAR MODEL; PARTICLE SIZE; PREDICTION; QUALITATIVE ANALYSIS; RELIABILITY; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VALIDATION PROCESS;

ANIMALS; COMPUTER-AIDED DESIGN; DRUG DESIGN; HUMANS; MATRIX METALLOPROTEINASES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 4444274979     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043387953     Document Type: Review

References (68)

1. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Curr. Med. Chem. 2001, 8, 425-474.
2. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Chem. Rev. 1999, 99, 2735-2776.
3. Michaelides, M. R.; Curtin, M. L. Recent Advances in Matrix Metalloproteinase Inhibitors Research. Curr. Pharm. Des. 1999, 5, 787-819.
4. White, A. D.; Bocan, M. A.; Boxer, P. A.; Peterson, J. T.; Schrier, D. Emerging Therapeutic Advances for the Development of Second Generation Matrix Metalloproteinase Inhibitors. Curr. Pharm. Des. 1997, 3, 45-58.
5. Beckett, R. P. Recent Advances in the Field of Matrix Metalloproteinase Inhibitors. Exp. Opin. Ther. Pat. 1996, 6, 1305-1315.
6. Beckett, R. P.; Davidson, A. H.; Drummond, A. H.; Whittaker, M. Recent Advances in Matrix Metalloproteinase Inhibitor Research. Drug Discov. Today 1996, 1, 16-26.
7. Kiyama, R.; Tamura, Y.; Watanabe, F.; Tsuzuki, H.; Ohtani, M.; Yodo, M. Homology Modeling of Gelatinase Catalytic Domains and Docking Simulations of Novel Sulfonamide Inhibitors. J. Med. Chem. 1999, 42, 1723-1738.
8. Johnson, L. L.; Bornemeier, D. A.; Janowicz, J. A.; Chen, J.; Pavlovsky, A. G.; Ortwine, D. F. Effect of Species Differences on Stromelysin-1 (MMP-3) Inhibitor Potency. An Explanation of Inhibitor Selectivity Using Homology Modeling and Chimeric Proteins. J. Biol. Chem. 1999, 274, 24881-24887.
9. Matter, H.; Schwab, W. Affinity and Selectivity of Matrix Metalloproteinase Inhibitors: A Chemometrical Study from the Perspective of Ligands and Proteins. J. Med. Chem. 1999, 42, 4506-4523.
10. Matter, H.; Schwab, W.; Barbier, D.; Billen, G.; Haase, B.; Neises, B.; Schudok, M.; Thorwart, W.; Schreuder, H.; Brachvogel, V.; Loenze, P.; Weithmann, K. U. Quantitative Structure-Activity Relationship of Human Neutrophil Collagenase (MMP-8) Inhibitors Using Comparative Molecular Field Analysis and X-ray Structure Analysis. J. Med. Chem. 1999, 42, 1908-1920.
11. Terp, G. E.; Christensen, I. T.; Jorgensen, F. S. Structural Differences of Matrix Metalloproteinases. Homology Modeling and Energy Minimization of Enzyme-Substrate Complexes. J. Biomol. Struct. Dyn. 2000, 17, 933-946.
12. Muegge, I.; Podlogar, B. L. 3D-Quantitative Structure Activity Relationships of Biphenyl Carboxylic Acid MMP-3 Inhibitors: Exploring Automated Docking as Alignment Method. QSAR 2001, 20, 215-222.
13. Amin, E. A.; Welsh, W. J. Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Models for a Novel Class of Piperazine-Based Stromelysin-1 (MMP-3) Inhibitors: Applying a " Divide and Conquer" Strategy. J. Med. Chem. 2001, 44, 3849-3855.
14. Terp, G. E.; Cruciani, G.; Christensen, I. T.; Jorgensen, F. S. Structural Differences of Matrix Metalloproteinases with Potential Implications for Inhibitor Selectivity Examined by the GRID/CPCA Approach. J. Med. Chem. 2002, 45, 2675-2684.
15. Cheng, F.; Zhang, R.; Luo, X.; Shen, J.; Li, X.; Gu, J.; Zhu, W.; Shen, J.; Sagi, I.; Ji, X.; Chen, K.; Jiang, H. Quantum Chemistry Study on the Interaction of the Exogenous Ligands and the Catalytic Zinc Ion in Matrix Metalloproteinases. J. Phys. Chem. 2002, 106, 4552-4559.
16. Hou, T.; Zhang, W.; Xu, X. Molecular Docking Studies of a Group of Hydroxamate Inhibitors with Gelatinase-A by Molecular Dynamics. J. Comput.Aided Mol. Des. 2002, 16, 27-41.
17. Grams, F.; Crimmin, M.; Hinnes, L.; Huxley, P.; Pieper, M.; Tschesche, H.; Bode, W. Structure Determination and Analysis of Human Neutrophil Collagenase Complexed with a Hydroxamate Inhibitor. Biochemistry 1995, 34, 14012-14020.
18. Gonnella, N. C.; Li, Y.-C.; Zhang, X.; Paris, C. G. Bioactive Conformation of a Potent Stromelysin Inhibitor Determined by X-Nucleus Filtered and Multidimensional NMR Spectroscopy. Bioorg. Med. Chem. 1997, 5, 2193-2201.
19. Li, Y.-C.; Zhang, X.; Melton, R.; Ganu, V.; Gonnella, N. C. Solution Structure of the Catalytic Domain of Human Stromelysin-1 Complexed to a Potent, Nonpeptidic Inhibitor. Biochemistry 1998, 37, 14048-14056.
20. Muri, E. M. F.; Nieto, M. J.; Sindelar, R. D.; Williamson, J. D. Hydroxamic Acids as Pharmacological Agents. Curr. Med. Chem. 2002, 9, 1631-1653.
21. Yang, K.; Lou, B. Molecular Diversity of Hydroxamic Acids: Part I. Solution- and Solid-Phase Synthesis. Mini. Rev. Med. Chem. 2003, 3, 349-360.
22. Campion, C.; Davidson, A. H.; Dickens, J. P.; Crimmin, M. J. Preparation of N-[4-(N-Hydroxyamino)succinyl]amino Acid Amides as Collagenases Inhibitors. PCT Int. Appl. WO 9005719, May 31, 1990.
23. Rasmussen, H. S.; McCann, P. P. Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy: a Review with Special Focus on Batimastat and Marimastat. Pharmacol. Ther. 1997, 75, 69-75.
24. Rasmussen, H. S. Batimastat and Marimastat in Cancer: Summary of Early Clinical Data. Antiangiogenic Agents in Cancer Therapy 1999, 399-405.
25. Nemunaitis, J.; Poole, C.; Primrose, J.; Rosemurgy, A.; Malfetano, J.; Brown, P.; Berrington, A.; Cornish, A.; Lynch, K.; Rasmussen, H.; Kerr, D.; Cox, D.; Millar, A. Combined Analysis of Studies of the Effects of the Matrix Metalloproteinase Inhibitor Marimastat on Serum Tumor Markers in Advanced Cancer: Selection of a Biologically Active and Tolerable Dose for Longer-Term Studies. Clin. Cancer Res. 1998, 4, 1101-1109.
26. Crimmin, M. J.; Ayscough, A. P.; Beckett, R. P. Preparation of Hydroxamic Acid Containing Amino Acid and Peptide as Metalloproteinase and Tumor Necrosis Factor Release Inhibitors. PCT Int. Appl. WO 9424140, Oct 27, 1994.
27. Broadhurst, M. J.; Brown, P. A.; Lawton, G.; Ballantyne, N.; Bottomley, K. M. K.; Cooper, M. I.; Eatherton, A. J.; Kifford, I. R.; Malsher, P. J.; Nixon, J. S.; Lewis, E. J.; Sutton, B. M.; Johnson, W. H. Design and Synthesis of the Cartilage Protective Agent (CPA, Ro 32-3555). Bioorg. Med. Chem. Lett. 1997, 7, 2299-2302.
28. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E. M.; Ganu, V.; Parker, D. T. Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits. J. Med. Chem. 1997, 40, 2525-2532.
29. Price, A.; Shi, Q.; Morris, D.; Wilcox, M. E.; Brasher, P. M. A.; Rewcastle, N. B.; Shalinsky, D.; Zou, H.; Appelt, K.; Johnston, R. N.; Yong, V. W.; Edwards, D.; Forsyth, P. Marked Inhibition of Tumor Growth in a Malignant Glioma Tumor Model by a Novel Synthetic Matrix Metalloproteinase Inhibitor AG3340. Clin. Cancer Res. 1999, 5, 845-854.
30. Shalinsky, D. R.; Brekken, J.; Zou, H.; Bloom, L. A.; McDermott, C. D.; Zook, S.; Varki, N. M.; Appelt, K. Marked Antiangiogenic and Antitumor Efficacy of AG3340 in Chemoresistant Human Non-Small-Cell Lung Cancer Tumors: Single Agent and Combination Chemotherapy Studies. Clin. Cancer Res. 1999, 5, 1905-1917.
31. Griffioen, A. W. AG-3340 Agouron Pharmaceuticals Inc. IDrugs 2000, 3, 336-345.
32. Zook, S. E.; Dagnino, R., Jr.; Deason, M. E.; Bender, S. L.; Melnick, M. J. Preparation of Heterocyclic Metalloproteinase-Inhibitor Antitumor Agents and Antiarthritics. PCT Int Appl. WO 9720824, June 06, 1997.
33. Almstead, N. G.; Bradley, R. S.; Pikul, S.; De, B.; Natchus, M. G.; Taiwo, Y. O.; Gu, F.; Williams, L. E.; Hynd, B. A.; Janusz, M. J.; Dunaway, C. M.; Mieling, G. E. Design, Synthesis, and Biological Evaluation of Potent Thiazine- and Thiazepine-Based Matrix Metalloproteinase Inhibitors. J. Med. Chem. 1999, 42, 4547-4562.
34. Cheng, M.; De, B.; Pikul, S.; Almstead, N. G.; Natchus, M. G.; Anastasio, M. V.; McPhail, S. J.; Snider, C. E.; Taiwo, Y. O.; Chen, L.; Dunaway, C. M.; Gu, F.; Dowly, M. E.; Mieling, G. E.; Janusz, M. J.; Wang-Weigand, S. Design and Synthesis of Piperazine-Based Matrix Metalloproteinase Inhibitors. J. Med. Chem. 2000, 43, 369-380.
35. Levin, J. I.; Du, M. T.; DiJoseph, J. F.; Killar, L. M.; Sung, A.; Walter, T.; Sharr, M. A.; Roth, C. E.; Moy, F. J.; Powers, R.; Jin, G.; Cowling, R.; Skotnicki, J. S. The Discovery of Anthranilic Acid-Based MMP Inhibitors. Part 1: SAR of the 3-Position. Bioorg. Med. Chem. Lett. 2001, 11, 235-238.
36. Levin, J. I.; Chen, J.; Du, M.; Hogan, M.; Kincaid, S.; Nelson, F. C.; Venkatesan, A. M.; Wehr, T.; Zask, A.; DiJoseph, J.; Killar, L. M.; Skala, S.; Sung, A.; Sharr, M.; Roth, C.; Jin, G.; Cowling, R.; Mohler, K. M.; Black, R. A.; March, C. J.; Skotnicki, J. S. The Discovery of Anthranilic Acid-Based MMP Inhibitors. Part 2: SAR of the 5-Position and P11 Groups. Bioorg. Med. Chem. Lett. 2001, 11, 2189-2192.
37. Freskos, J. N.; McDonald, J. J.; Mischke, B. V.; Mullins, P. B.; Shieh, H.-S.; Stegeman, R. A.; Stevens, A. M. Synthesis and Identification of Conformationally Constrained Selective MMP Inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 1757-1760.
38. Rockwell, A.; Melden, M.; Copeland, E. A.; Hardman, K.; Decicco, C. P.; DeGrado, W. F. Complementarity of Combinatorial Chemistry and Structure-Based Ligand Design - Application to the Discovery of Novel Inhibitors of Matrix Metalloproteinases. J. Am. Chem. Soc. 1996, 118, 10337-10338.
39. Bird, J.; Montana, J. G.; Wills, R. E.; Baxter, A. D.; Owen, D. A. Selective Matrix Metalloproteinase (MMP) Inhibitors Having Reduced Side-Effects. PCT Int. Appl. WO 9839024, Sept 11, 1998.
40. Campbell, J. A.; Van Hart, H.; Caufield, J. P.; Eugie, E.; Womble, S.; Martin, R.; Browner, M.; Brandl, M.; Fischer, L.; Masjedizadeh, M.; Castelhano, A.; Broka, C.; Hendricks, R. T.; Walker, R. 216th A.C.S. Meeting, Boston, MA, 1998, MEDI 4.
41. Hanessian, S.; Griffin, A.; Devasthale, P. V. Synthesis of Conformationally Constrained Potential Inhibitors of Mammalian Metalloproteinases. Bioorg. Med. Chem. Lett. 1997, 7, 3119-3124.
42. Hanessian, S.; Moitessier, N.; Wilmouth, S. Tetrahydrofuran as a Scaffold for Peptidomimetics. Application to the Design and Synthesis of Conformationally Constrained Metalloproteinase Inhibitors. Tetrahedron 2000, 56, 8469-8485.
43. Hanessian, S.; Johnstone, S. Synthesis of Hydroxamic Esters via Alkoxyamiocarbonylation of α-Dicarbonyl Compounds. J. Org. Chem. 1999, 64, 5896-5903.
44. For other malonic acid based MMP inhibitors, see: von Roedern, E. G.; Brandstetter, H.; Engh, R. A.; Bode, W.; Grams, F.; Moroder, L. Bis-Substituted Malonic Acid Hydroxamate Derivatives as Inhibitors of Human Neutrophil Collagenase (MMP-8). J. Med. Chem. 1998, 41, 3041-3047.
45. Martin, S. F.; Oalmann, C. J.; Liras, S. Cyclopropanes as Conformationally Restricted Peptides Isosters. Design and Synthesis of Novel Collagenase Inhibitors. Tetrahedron 1993, 49, 3521-3532.
46. Reichelt, A.; Gaul, C.; Frey, R. R.; Kennedy, A.; Martin, S. F. Design, Synthesis, and Evaluation of Matrix Metalloprotease Inhibitors Bearing Cyclopropane-Derived Peptidomimetics as P1′ and P2′ Replacements. J. Org. Chem. 2002, 67, 4062-4075.
47. 2′ subsite: Natchus, M. G.; Cheng, M.; Wahl, C. T.; Pikul, S.; Almstead, N. G.; Bradley, R. S.; Taiwo, Y. O.; Mieling, G. E.; Dunaway, C. M.; Snider, C. E.; McIver, J. M.; Barnett, B. L.; McPhail, S. J.; Anastasio, M. B.; De, B. Design and Synthesis of Conformationally Constrained MMP Inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 2077-2080.
48. Duan, J. J.-W.; Chen, L.; Xue, C.-B.; Wasserman, Z. R.; Hardman, K. D.; Covington, M. B.; Copeland, R. R.; Amer, E. C.; Decicco, C. P. P1, P2′-Linked Macrocyclic Amine Derivatives as Matrix Metalloproteinase Inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 1453-1458.
49. Lou, B.; Huynh, H. K.; Hanessian, S. In Preparative Carbohydrate Chemistry; Hanessian S., Ed.; Dekker: New York, 1996, Chapter 19, 431.
50. 2′ Pockets of Matrix Metalloproteinases. A Niche for Potent Acyclic Sulfonamide Inhibitors. Bioorg. Med Chem. Lett. 1999, 9, 1691-1696.
51. 2′ Pockets. J. Med. Chem. 2001, 44, 3066-3073.
52. Hanessian, S.; Moitessier, N.; Gauchet, C.; Hickman, J.; Tucker, G.; Caignard, D.-H.; Renard, P. Nouveaux Dérivés d'Acide Hydroxamique, leur Procédé de Préparation et les Compositions Pharmaceutiques qui les Contiennent. Fr. Patent, FR 2819253, 2001.
53. A similar appraoch was recently reported: Fujisawa, T.; Igeta, K.; Odake, S.; Morita, Y.; Yasuda, J.; Morikawa, T. Highly Water-Soluble Matrix Metalloproteinases Inhibitors and Their Effects in a Rat Adjuvant-Induced Arthitis Model. Bioorg. Med. Chem. 2002, 10, 2569-2581.
54. Esser, C. K; Bugianesi, R. L.; Caldwell, C. G.; Chapman, K. T.; Durette, P. L.; Girotra, N. N.; Kopka, I. E.; Lanza, T. J.; Levorse, D. A.; MacCoss, M.; Owens, K. A.; Ponpipom, M. M.; Simeone, J. P.; Harrison, R. K.; Niedzwiecki, L.; Becker, J. W.; Marcy, A. I.; Axel, M. G.; Christen, A. J.; McDonnell, J.; Moore, V. L.; Olszewski, J. M.; Saphos, C.; Visco, D. M.; Shen, F.; Colleti, A.; Krieter, P. A.; Hagmann, W. K. Inhibition of Stromelysin-1 (MMP-3) by P1′-Biphenylylethyl Carboxyalkyl Dipeptides. J. Med. Chem. 1997, 40, 1026-1040.
55. Hanessian, S.; Moitessier, N.; Therrien, E. A Comparative Docking Study and the Design of Potentially Selective MMP Inhibitors. J. Comput.Aided Mol. Des. 2001, 15, 873-881.
56. Hanessian, S.; Moitessier, N.; Cantin, L.-D. Design and Synthesis of MMP Inhibitors using N-Arylsulfonylaziridine Hydroxamic Acids as Constrained Scaffolds. Tetrahedron 2001, 57, 6885-6900.
57. 1 Pocket Using Conformationally Constrained Inhibitors. J. Med. Chem. 2001, 44, 3074-3082.
58. Hanessian, S.; Moitessier, N.; MacKay, B.; Hickman, J.; Tucker, G.; Caignard, D.-H.; Renard, P. Nouveaux Dérivés d'Acide Hydroxamique, leur Procédé de Préparation et les Compositions Pharmaceutiques qui les Contiennent. Fr. Patent, FR 2819252, 2001.
59. 1′ Pocket Mutation in Matrylisin and Stromelysin-1. Biochemistry 1996, 35, 10103-10109.
60. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A Geometric Approach to Macromolecule-Ligand Interactions. J. Mol. Biol. 1982, 161, 269-288.
61. Kuntz, I.D. Structure-Based Strategies for Drug Design and Discovery. Science 1992, 257, 1078-1082.
62. Ewing, T. J. A.; Kuntz, I. D. Critical Evaluation of Search Algorithms for Automated Molecular Docking and Database Screening. J. Comput. Chem. 1997, 18, 1175-1189.
63. Goodsell, D. S.; Olson, A.J. Automated Docking of Substrates to Proteins by Simulated Annealing. Proteins. Struct. Func. Genet. 1990, 8, 195-202.
64. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated Docking (Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
65. Ha, S.; Andreani, R.; Robbins, A.; Muegge, I. Evaluation of Docking/Scoring Approaches: a Comparative Study Based on MMP3 Inhibitors. J. Comput.Aided Mol. Des. 2000, 14, 435-448.
66. Hanessian S.; Andreotti, D.; Gomtsyan, A. Asymmetric Synthesis of Enantiomerically Pure and Diversely Functionalized Cyclopropanes. J. Am. Chem. Soc. 1995, 117, 10393-10394.
67. Hanessian, S.; Cantin, L.-D. The Synthesis of Enantiomerically Pure Disubstituyed Aziridines and N-Alkoxyaziridines. Tetrahedron Lett. 2000, 41, 787-790.
68. Cardillo, G.; Casolari, S.; Gentilucci, L.; Tomasini, C. Asymmetric Synthesis of Alkyl-Aziridine-2-Carboxylates from Chiral 3′-benzyloxyaminoimides. Angew. Chem., Int. Ed. Engl. 1996, 35, 1848-1849.